MAPT and Alzheimer disease: Although all the patients included in the sample met the MCI diagnosis criteria (Petersen, 2004), the lack of neuropathological markers of AD (i.e., CSF/PET amyloid or tau markers) potentially increases the heterogeneity of the MCI population and could diminish the degree of association between VCI and AD that we can state with our data.